Everest Re Group, Ltd.

(New York Stock Exchange)
Back to all articles
Bullish +65

Everest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100

AI-generated analysis

🀝 Everest Medicines secured an exclusive license from Corxel Pharmaceuticals for LNZ100 eye drops in Greater China.

πŸ’° The deal structure includes upfront payments, regulatory milestones, sales milestones, and tiered royalties.

πŸ‘οΈ LNZ100 is a once-daily prescription eye drop designed to treat presbyopia by improving near vision.

πŸ‡¨πŸ‡³ A New Drug Application for China has been submitted with approval expected in 2027.

πŸ“ˆ The therapy targets the mid-40s to mid-70s demographic with a large unmet need in the region.

πŸ”¬ LNZ100 uses aceclidine to induce a pinhole pupil while preserving distance vision capabilities.

πŸš€ This acquisition expands Everest's innovative pipeline and strengthens its ophthalmology portfolio.

πŸ“Š The most recent analyst rating on Everest Medicines stock is currently a Hold.

Bullish Signals
  • Everest Medicines has secured an exclusive license for LNZ100 in Greater China, expanding its geographic reach and product pipeline.
  • The deal includes upfront payments and potential tiered royalties, providing immediate financial upside and future revenue streams.
  • LNZ100 is already approved and launched in the United States, reducing regulatory risk for the Chinese market entry.
  • Regulatory approval in China is expected in 2027, offering a clear timeline for commercialization of a novel therapy.
  • The drug addresses a significant unmet medical need in the large presbyopic population from mid-40s to mid-70s.
  • This strategic partnership deepens Everest's positioning in the high-growth ophthalmology sector.
Full Analysis
Everest Medicines Ltd. (HK:1952) has secured an exclusive license from Corxel Pharmaceuticals to develop, manufacture, and commercialize LNZ100, a once-daily prescription eye drop for presbyopia, across Greater China. The agreement includes an upfront payment, regulatory and sales milestones, and tiered royalties, aiming to expand Everest's innovative pipeline and strengthen its position in the ophthalmology sector. LNZ100, which utilizes aceclidine to improve near vision by inducing a pinhole pupil while preserving distance vision, is already approved and launched in the United States. A New Drug Application has been submitted for China, with regulatory approval expected in 2027. This therapy targets a large unmet need in the Chinese market, potentially serving patients from their mid-40s to mid-70s. This strategic move is intended to deepen Everest's positioning in ophthalmology and create broader synergies across its business. The company focuses on bringing innovative therapies to patients in Greater China through in-licensing and partnerships to address significant unmet medical needs in the region.